Latest Conference Articles

November 17th 2021, 10:03pm

NANETS Symposium

Daneng Li, MD, discusses the interim analysis results of a phase 1 trial evaluating surufatinib in United States patients with neuroendocrine tumors.

November 17th 2021, 10:01pm

NANETS Symposium

Diane Reidy-Lagunes, MD, discusses the results of the phase 3 SPINET trial by tumor subtype in bronchopulmonary neuroendocrine tumors.

November 16th 2021, 6:47pm

NANETS Symposium

Surufatinib demonstrated a comparable health-related quality of life with placebo in patients with advanced neuroendocrine tumors.

November 16th 2021, 2:10pm

SITC Meeting

Concurrent treatment with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia who were receiving lisocabtagene maraleucel led to measurable effects in both CAR+ and endogenous T cells, both of which were linked with improved efficacy.

November 15th 2021, 8:25pm

T-cell inflamed gene expression profile and tumor mutational burden assessment was found to be a feasible approach to study the clinical activity of 3 pembrolizumab-based combination regimens in treatment-naïve patients with advanced non–small cell lung cancer.

November 15th 2021, 7:33pm

NANETS Symposium

Tidutamab was found to be well tolerated with a best overall response of stable disease in patients with advanced, well-differentiated neuroendocrine tumors of pancreatic, gastrointestinal, lung and undetermined origin.

November 15th 2021, 6:58pm

SITC Meeting

The COVID-19 vaccine was safe and well tolerated in patients who received immune checkpoint inhibitors for renal cell carcinoma or melanoma.

November 15th 2021, 6:05pm

SITC Meeting

The combination of lenvatinib plus pembrolizumab induced durable responses with a manageable safety profile in adults with previously treated, advanced endometrial cancer, according to a long-term follow-up analysis of a phase 1b/2 study (NCT02501096).

November 15th 2021, 4:08pm

SITC Meeting

ICT01, a humanized anti-BTN3A monoclonal antibody that selectively activates γ9δ2 T cells, has demonstrated early signs of biological activity when given as a single agent or in combination with pembrolizumab in patients with advanced solid tumors.

November 15th 2021, 3:00pm

NANETS Symposium

The combination of pembrolizumab (Keytruda) and irinotecan- or paclitaxel-based chemotherapy was not found to be effective in pretreated, biomarker-unselected patients with extrapulmonary poorly differentiated neuroendocrine carcinomas.

November 15th 2021, 2:00pm

NANETS Symposium

Patients with carcinoid syndrome reported improved symptoms following treatment with telotristat ethyl.

November 13th 2021, 11:00am

NANETS Symposium

The combination of surufatinib and toripalimab demonstrated promising clinical activity with a manageable safety profile when used as second-line treatment for patients with advanced neuroendocrine carcinoma.

November 12th 2021, 9:14pm

SITC Meeting

The combination of eftilagimod alpha and paclitaxel produced a modest increase in median overall survival in patients with endocrine-resistant hormone receptor–positive/HER2-negative metastatic breast cancer. Though, the effects were significant in patients younger than 65 years old, had low monocytes, or had more aggressive disease.

November 12th 2021, 9:00pm

SITC Meeting

ATG-101, a novel PD-L1/4-1BB bispecific antibody, demonstrated good in vivo efficacy, safety without hepatotoxicity, and pharmacokinetic/pharmacodynamic properties in cynomolgus monkeys.

November 12th 2021, 8:26pm

SITC Meeting

The innate cell engager AFM24 showed greater efficacy in eliciting antibody-dependent cellular phagocytosis of EGFR wild-type and KRAS-mutant tumor cells compared with cetuximab.

November 12th 2021, 7:55pm

SITC Meeting

The DuoBody®-CD3x5T4 was found to induce secretion of granzyme B and efficiently kill tumor cells in co-cultures of healthy donor T cells and patient-derived head and neck squamous cell carcinoma cell lines.

November 12th 2021, 5:00pm

NANETS Symposium

Surufatinib demonstrated strong antitumor activity along with a manageable safety profile in heavily treated US patients with progressive extrapancreatic neuroendocrine tumors or pancreatic NETs, according to interim phase 1 data.

November 10th 2021, 4:00pm

NANETS Symposium

The small molecule drug conjugate PEN-221 was generally well tolerated and elicited significant clinical benefit in patients with pretreated gastrointestinal neuroendocrine tumors.

November 8th 2021, 9:08pm

PER® New York Lung Cancer Symposium

Ashish Saxena, MD, PhD, discusses a challenging case of a patient with non–small cell lung cancer.

November 8th 2021, 9:04pm

PER® New York Lung Cancer Symposium

Marjorie G. Zauderer, MD, discusses the importance of optimizing care for patients with mesothelioma.